Cwm, LLC Biomarin Pharmaceutical Inc Transaction History

Cwm, LLC

$28.4 Billion
Q2 2025

A detailed history of Cwm, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Cwm, LLC holds 87,955 shares of BMRN stock, worth $5.11 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

87,955

Previous 60,061 46.44%

Holding current value

$5.11 Million

Previous $4.25 Million 13.87%

% of portfolio

0.02%

Previous 0.02%

36 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 25, 2025	BUY	$54.08 - $68.32 $1.51 Million - $1.91 Million	27,894 Added 46.44%	87,955 $4.84 Million
Q1 2025 May 01, 2025	BUY	$61.25 - $72.83 $2.07 Million - $2.46 Million	33,746 Added 128.24%	60,061 $4.25 Million
Q4 2024 Feb 04, 2025	BUY	$61.93 - $70.49 $941,893 - $1.07 Million	15,209 Added 136.94%	26,315 $1.73 Million
Q3 2024 Oct 08, 2024	BUY	$69.02 - $93.84 $601,026 - $817,158	8,708 Added 363.14%	11,106 $781,000
Q2 2024 Jul 09, 2024	BUY	$74.43 - $92.22 $72,569 - $89,914	975 Added 68.52%	2,398 $197,000
Q1 2024 Apr 05, 2024	SELL	$83.81 - $99.0 $3,520 - $4,158	-42 Reduced 2.87%	1,423 $124,000
Q4 2023 Feb 01, 2024	BUY	$76.22 - $98.51 $12,500 - $16,155	164 Added 12.61%	1,465 $141,000
Q3 2023 Oct 11, 2023	BUY	$85.07 - $94.48 $10,038 - $11,148	118 Added 9.97%	1,301 $115,000
Q2 2023 Aug 03, 2023	BUY	$86.68 - $100.3 $18,896 - $21,865	218 Added 22.59%	1,183 $103,000
Q1 2023 Apr 28, 2023	BUY	$87.74 - $117.27 $3,246 - $4,338	37 Added 3.99%	965 $94,000
Q4 2022 Feb 01, 2023	SELL	$80.93 - $108.63 $161 - $217	-2 Reduced 0.22%	928 $96,000
Q3 2022 Oct 27, 2022	BUY	$82.16 - $96.94 $12,241 - $14,444	149 Added 19.08%	930 $79,000
Q2 2022 Jul 28, 2022	BUY	$71.48 - $86.85 $21,015 - $25,533	294 Added 60.37%	781 $65,000
Q1 2022 Apr 21, 2022	BUY	$74.28 - $92.69 $29,414 - $36,705	396 Added 435.16%	487 $38,000
Q4 2021 Jan 31, 2022	BUY	$71.72 - $91.47 $4,159 - $5,305	58 Added 175.76%	91 $8,000
Q1 2021 Sep 15, 2021	BUY	$74.73 - $90.69 $2,466 - $2,992	33 New	33 $3,000
Q1 2021 Apr 27, 2021	SELL	$74.73 - $90.69 $2,466 - $2,992	-33 Closed	0 $0
Q4 2020 Sep 15, 2021	BUY	$72.61 - $90.2 $2,396 - $2,976	33 New	33 $3,000
Q4 2020 Jan 27, 2021	SELL	$72.61 - $90.2 $2,396 - $2,976	-33 Closed	0 $0
Q3 2020 Sep 15, 2021	SELL	$71.87 - $131.03 $15,667 - $28,564	-218 Reduced 86.85%	33 $3,000
Q3 2020 Oct 19, 2020	BUY	$71.87 - $131.03 $15,667 - $28,564	218 Added 660.61%	251 $19,000
Q2 2020 Sep 15, 2021	SELL	$79.55 - $124.22 $5,170 - $8,074	-65 Reduced 66.33%	33 $3,000
Q2 2020 Jul 22, 2020	BUY	$79.55 - $124.22 $5,170 - $8,074	65 Added 196.97%	98 $12,000
Q1 2020 Sep 15, 2021	BUY	$71.37 - $96.85 $2,355 - $3,196	33 New	33 $3,000
Q1 2020 Apr 28, 2020	SELL	$71.37 - $96.85 $2,355 - $3,196	-33 Closed	0 $0
Q4 2019 Sep 14, 2021	SELL	$64.27 - $86.37 $13,175 - $17,705	-205 Reduced 86.13%	33 $3,000
Q4 2019 Jan 27, 2020	BUY	$64.27 - $86.37 $13,175 - $17,705	205 Added 621.21%	238 $20,000
Q3 2019 Sep 14, 2021	BUY	$67.4 - $85.11 $1,213 - $1,531	18 Added 120.0%	33 $3,000
Q3 2019 Oct 22, 2019	SELL	$67.4 - $85.11 $1,213 - $1,531	-18 Reduced 54.55%	15 $1,000
Q2 2019 Sep 14, 2021	SELL	$80.35 - $93.9 $2,731 - $3,192	-34 Reduced 50.75%	33 $3,000
Q2 2019 Jul 31, 2019	BUY	$80.35 - $93.9 $2,731 - $3,192	34 Added 103.03%	67 $6,000
Q1 2019 Sep 02, 2021	SELL	$84.2 - $98.62 $3,283 - $3,846	-39 Reduced 54.17%	33 $0
Q1 2019 Apr 22, 2019	BUY	$84.2 - $98.62 $3,957 - $4,635	47 Added 188.0%	72 $6,000
Q4 2018 Jan 25, 2019	BUY	$80.14 - $106.07 $2,003 - $2,651	25 New	25 $2,000
Q1 2018 Apr 26, 2018	SELL	$77.67 - $92.63 $3,961 - $4,724	-51 Closed	0 $0
Q3 2017 Oct 16, 2017	BUY	$80.6 - $94.95 $4,110 - $4,842	51	51 $5,000

Others Institutions Holding BMRN

# of Institutions

668

Shares Held

185M

Call Options Held

1.25M

Put Options Held

992K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account